生物治疗在儿科过敏和呼吸道疾病中的新机遇。
New opportunities with biologic treatments in pediatric allergic and respiratory diseases.
机构信息
Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Clinic, University of Verona, Verona, Italy.
出版信息
Pediatr Allergy Immunol. 2022 Jan;33 Suppl 27(Suppl 27):8-10. doi: 10.1111/pai.13617.
Abstract
In the last 20 years, the introduction of monoclonal antibodies has dramatically changed allergic diseases. At present, several monoclonal antibodies are approved for treating asthma, atopic dermatitis, chronic spontaneous urticaria, and chronic sinusitis with nasal polyps in children. Biologics have also changed the management of these diseases in the pediatric population, tending toward personalized medicine based on the type-2 inflammatory pattern.
摘要
在过去的 20 年中，单克隆抗体的引入极大地改变了过敏疾病。目前，有几种单克隆抗体被批准用于治疗儿童哮喘、特应性皮炎、慢性自发性荨麻疹和伴有鼻息肉的慢性鼻-鼻窦炎。生物制剂也改变了儿科人群对这些疾病的管理方式，倾向于根据 2 型炎症模式进行个体化治疗。
相似文献
1
New opportunities with biologic treatments in pediatric allergic and respiratory diseases.生物治疗在儿科过敏和呼吸道疾病中的新机遇。
Pediatr Allergy Immunol. 2022 Jan;33 Suppl 27(Suppl 27):8-10. doi: 10.1111/pai.13617.
2
Biologics in allergic and immunologic diseases: Promises and challenges in the era of personalized medicine.生物制剂在过敏性和免疫性疾病中的应用：个性化医疗时代的前景与挑战
Ann Allergy Asthma Immunol. 2018 Apr;120(4):350-353. doi: 10.1016/j.anai.2018.01.032. Epub 2018 Feb 5.
3
Uses of biologics in allergic diseases: What to choose and when.生物制剂在过敏性疾病中的应用：如何选择及何时使用。
Ann Allergy Asthma Immunol. 2018 Apr;120(4):357-366. doi: 10.1016/j.anai.2018.02.029. Epub 2018 Feb 27.
4
Strategies for choosing a biologic for your patient with allergy or asthma.治疗过敏或哮喘患者的生物制剂选择策略。
Ann Allergy Asthma Immunol. 2021 Dec;127(6):627-637. doi: 10.1016/j.anai.2021.09.009. Epub 2021 Sep 23.
5
Biologics.生物制剂
Ann Allergy Asthma Immunol. 2018 Apr;120(4):354-356. doi: 10.1016/j.anai.2018.02.030.
6
Targeted Molecular Therapies in Allergy and Rhinology.变应性和鼻科学中的靶向分子治疗。
Otolaryngol Head Neck Surg. 2021 Jan;164(1_suppl):S1-S21. doi: 10.1177/0194599820965233. Epub 2020 Nov 3.
7
Biologics and biomarkers for asthma, urticaria, and nasal polyposis.哮喘、荨麻疹和鼻息肉的生物制剂和生物标志物。
J Allergy Clin Immunol. 2017 May;139(5):1411-1421. doi: 10.1016/j.jaci.2017.03.006.
8
Cost-Effectiveness of Biologics for Allergic Diseases.生物制剂治疗过敏性疾病的成本效益分析。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1107-1117.e2. doi: 10.1016/j.jaip.2020.10.009. Epub 2020 Oct 15.
9
Biologics for Asthma and Allergic Skin Diseases in Children.儿童哮喘和过敏性皮肤病的生物制剂
Pediatrics. 2021 Nov 1;148(5). doi: 10.1542/peds.2021-054270. Epub 2021 Oct 18.
10
A Review of Adverse Reactions to Biologics Used in Allergy-Immunology Practice.过敏免疫实践中使用的生物制剂不良反应综述。
J Allergy Clin Immunol Pract. 2022 Dec;10(12):3075-3086. doi: 10.1016/j.jaip.2022.09.020. Epub 2022 Sep 23.
引用本文的文献
1
A novel mutation in GAS8 gene associated with chronic rhinosinusitis with nasal polyposis in a case of primary ciliary dyskinesia: a case report.原发性纤毛运动障碍患者中与伴鼻息肉的慢性鼻-鼻窦炎相关的GAS8基因新突变：病例报告
Front Pediatr. 2024 May 30;12:1345265. doi: 10.3389/fped.2024.1345265. eCollection 2024.
2
Severe pediatric asthma therapy: Dupilumab.重度小儿哮喘治疗：度普利尤单抗。
Front Pediatr. 2022 Nov 22;10:963610. doi: 10.3389/fped.2022.963610. eCollection 2022.
本文引用的文献
1
Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review.重度难治性哮喘儿童及青少年的生物治疗：实用综述
Biologics. 2021 May 5;15:133-142. doi: 10.2147/BTT.S252574. eCollection 2021.
2
Anti-IL-5 in pediatric allergic diseases.抗白细胞介素-5 在儿科变应性疾病中的作用。
Pediatr Allergy Immunol. 2020 Nov;31 Suppl 26:14-16. doi: 10.1111/pai.13374.
3
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.度普利尤单抗治疗哮喘和常年性变应性鼻炎患者的临床结局疗效。
Ann Allergy Asthma Immunol. 2020 Nov;125(5):565-576.e1. doi: 10.1016/j.anai.2020.05.026. Epub 2020 May 28.
4
Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents.度普利尤单抗治疗儿童和青少年 2 型炎症性疾病。
Paediatr Drugs. 2020 Jun;22(3):295-310. doi: 10.1007/s40272-020-00387-2.
5
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma.度普利尤单抗治疗重度哮喘的疗效与安全性：对欧洲变态反应和临床免疫学会（EAACI）指南——重度哮喘生物制剂使用建议的系统评价
Allergy. 2020 May;75(5):1058-1068. doi: 10.1111/all.14268. Epub 2020 Apr 1.
6
Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.孟鲁司特钠联合布地奈德治疗儿童哮喘的临床疗效观察
J Allergy Clin Immunol. 2019 Nov;144(5):1336-1342.e7. doi: 10.1016/j.jaci.2019.08.005. Epub 2019 Aug 16.
7
Lung eosinophils-A novel "virus sink" that is defective in asthma?肺嗜酸性粒细胞——一种在哮喘中存在缺陷的新型“病毒库”？
Allergy. 2019 Oct;74(10):1832-1834. doi: 10.1111/all.13811.
8
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.度普利尤单抗在吸入中至高剂量皮质类固醇激素联合长效β2 激动剂治疗控制不佳的持续性哮喘成人患者中的疗效和安全性：一项随机、双盲、安慰剂对照的 2b 期关键剂量范围研究。
Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27.
9
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.美泊利珠单抗在嗜酸性粒细胞性哮喘中的口服糖皮质激素节省作用。
N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.
10
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.美泊利单抗治疗严重嗜酸性粒细胞性哮喘（DREAM）：一项多中心、双盲、安慰剂对照试验。
Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X.
Zotero 插件